Cardiovascular Inflammaging and Immunosenescence: Mechanisms, Biomarkers, and Therapeutic Targets

Cardiovascular disease (CVD) increases sharply with age, and growing evidence shows that chronic low-grade inflammation (“inflammaging”) and age-related immune dysfunction (“immunosenescence”) are central drivers of vascular aging, atherosclerosis, heart failure, and related conditions. Persistent immune activation, accumulation of senescent cells, and qualitative changes in immune cell populations reshape the cardiovascular microenvironment and influence disease onset, progression, and therapy response.At the same time, advances in multi-omics, single-cell technologies, and imaging now allow a more precise characterization of inflammatory and immune signatures in older individuals, opening opportunities for biomarker discovery and targeted interventions. Senolytics, anti-inflammatory and immunomodulatory therapies, as well as lifestyle-based strategies, hold promise but require deeper mechanistic understanding and better patient stratification.This Research Topic aims to integrate mechanistic, translational, and clinical perspectives on cardiovascular inflammaging and immunosenescence. We welcome original research, reviews, mini-reviews, and perspectives, particularly focusing on the following high-impact areas:Mechanistic links between inflammaging, immunosenescence, and major cardiovascular conditions (atherosclerosis, vascular stiffness, heart failure, arrhythmias).Role of senescent cells and SASP in vascular and myocardial remodeling, plaque instability, and microvascular dysfunction.Innate and adaptive immune remodeling in aging (e.g., monocyte/macrophage shifts, T cell exhaustion, altered B cell function) and its impact on cardiovascular risk.Biomarkers of cardiovascular inflammaging, including inflammatory mediators, immune cell phenotypes, and multi-omics signatures for risk prediction and patient stratification.Therapeutic strategies targeting inflammaging and immunosenescence, such as senolytics, anti-inflammatory and immunomodulatory agents, and combined pharmacological–lifestyle interventions.Precision and personalized approaches that integrate immune and inflammatory biomarkers into clinical decision-making for older patients with or at risk for CVD.This Topic aims to stimulate interdisciplinary collaboration to better understand and ultimately modulate inflammaging and immunosenescence for healthier cardiovascular aging. Topic editors: Maria Luisa Barcena Source: https://www.frontiersin.org/research-topics/75989/cardiovascular-inflammaging-and-immunosenescence-mechanisms-biomarkers-and-therapeutic-targets